LEIDEN, Netherlands, March 16, 2023 /PRNewswire/ -- Total revenues increased by 3% to US$205.6 million, in line with single digit growth guidanceOperating profit increased by 34% to US$18.2

Related Keywords

Australia , Japan , United States , Netherlands , United Kingdom , Israel , Sweden , Canada , London , City Of , Amsterdam , Noord Holland , America , Swedish , American , Dennis Riedl , Michael Levitan , Heather Robertson , Foster Mitchell Alex Shaw , Silicon Valley Bank , Us Centers For Disease , International Classification Of Diseases , Swedish Orphan International , Linkedin , Vp Investor Relations Corporate Communications , Ministry Of Health , Swedish Orphan International Ab Sobi , Committee For Human Medicinal Products , Nasdaq , American Society Of Hematology , Clinical Immunology Society , Lifespring Life Sciences Communication , Company Euronext Amsterdam , Bausch Health , American Society Hematology , European Commission Decision Reliance Procedure , Drug Administration , Regulatory Agency , Exchange Commission , Pharming Groupnv , European Medicines Agency , Pharming Group , Investor Relations Corporate Communications , Euronext Amsterdam , Executive Officer , Sijmen De Vries , American Society , European Economic Area , New Drug Application , Prescription Drug User Fee Act , Disease Control , International Classification , Clinical Modification , Activated Phosphoinositide , Delta Syndrome , Human Medicinal Products , Orphan Drug Designation , Pediatric Investigation Plan , Promising Innovative Medicine , Orchard Therapeutics , Investigational New Drug , Silicon Valley , Gross Profit , Fair Value Through , North American , Acute Kidney Injury , Pivot Park , General Meeting , Investor Relations , Corporate Communications , Spring Life Sciences Communication , North America , Middle East , Annual Report , Consolidated Financial Statements , Pharming , Group , Reports , Financial , Results , Bull , Ear , 022 ,